EX-99.1 2 exhibit991-q417pressrelease.htm EXHIBIT 99.1 Exhibit


Exhibit 99.1
 

Agilent Technologies Reports Fourth-Quarter Fiscal Year 2017 Financial Results

Agilent Caps Stellar Year with Strong Q4 Results

Highlights:

•
GAAP net income of $177 million, or $0.54 per share
•
Non-GAAP net income of $218 million, or $0.67 per share(1), $0.06 above midpoint guidance of $0.61 per share
•
Revenue of $1.19 billion, representing growth of 7.1 percent (core revenue growth of 5.8 percent(2) versus midpoint guidance of 3.5 percent)
•
First-quarter fiscal year 2018 revenue guidance of $1.145 billion to $1.165 billion and non-GAAP earnings guidance of $0.55 to $0.57 per share(3) 
•
Fiscal year 2018 revenue guidance of $4.720 billion to $4.740 billion and non-GAAP earnings guidance of $2.50 to $2.56 per share(3) 
•
Fiscal year 2018 operating cash flow guidance of $970 million

SANTA CLARA, Calif., November 20, 2017

Agilent Technologies, Inc. (NYSE: A) today reported revenue of $1.19 billion for the fourth-quarter ended October 31, 2017, up 7.1 percent year over year (up 5.8 percent on a core basis(2)).

Fourth-quarter GAAP net income was $177 million, or $0.54 per share. Last year’s fourth-quarter GAAP net income was $126 million, or $0.38 per share.

During the fourth quarter, Agilent had intangible amortization of $28 million, transformation costs of $7 million and acquisition and integration costs of $5 million. Excluding these items and a tax expense of $1 million, Agilent reported fourth-quarter non-GAAP net income of $218 million, or $0.67 per share(1).

“We ended fiscal 2017 with another strong quarter of revenue and profit growth,” said Mike McMullen, Agilent CEO and President. “Every quarter this year we have delivered strong revenue growth, expanded operating margins and increased non-GAAP earnings per share. Our consistently excellent financial performance demonstrates our sustained ability to win in the marketplace, while also driving operational improvements.”

“We are successfully executing our strategy positioning Agilent for future growth,” he added. “We continue strengthening our portfolio through our own R&D investment and M&A, bringing new capabilities and highly differentiated products to our customers. We have positive momentum heading into fiscal year 2018, and will continue our focus on driving sustainable above-market growth and delivering value to shareholders.”

Fourth-quarter revenue of $575 million from Agilent’s Life Sciences and Applied Markets Group (LSAG) grew 5 percent year over year (up 4 percent on a core basis(2)), with strength in chemical and energy, academia and government and food end markets. LSAG’s operating margin for the quarter was 23.9 percent.

Fourth-quarter revenue of $404 million from Agilent CrossLab Group (ACG) grew 9 percent year over year (up 8 percent on a core basis(2)). Growth was healthy across services and consumables, most regions and end markets. ACG’s operating margin for the quarter was 22.9 percent.

1



Fourth-quarter revenue of $210 million from Agilent’s Diagnostics and Genomics Group (DGG) grew 9 percent year over year (up 7 percent on a core basis(2)) led by increasing demand for pathology products and companion diagnostics services. DGG’s operating margin for the quarter was 20.8 percent.

Agilent expects first-quarter 2018 revenue in the range of $1.145 billion to $1.165 billion. First-quarter 2018 non-GAAP earnings are expected to be in the range of $0.55 to $0.57 per share(3).

For fiscal year 2018, Agilent expects revenue of $4.720 billion to $4.740 billion and non-GAAP earnings of $2.50 to $2.56 per share(3). The guidance is based on October 31, 2017, currency exchange rates.

Conference Call

Agilent’s management will present more details about its fourth-quarter FY2017 financial results on a conference call with investors today at 1:30 p.m. PT. This event will be webcast live in listen-only mode. Listeners may log on at www.investor.agilent.com and select “Q4 2017 Agilent Technologies Inc. Earnings Conference Call” in the “News & Events Calendar of Events” section. The webcast will remain available on the company’s website for 90 days.

Additional information regarding financial results can be found at www.investor.agilent.com by selecting “Financial Results” in the “Financial Information” section.

A telephone replay of the conference call will be available at approximately 4:30 p.m. PST today through November 27 by dialing +1 855-859-2056 (or +1 404-537-3406 from outside the United States) and entering pass code 2283927.

About Agilent Technologies
Agilent Technologies Inc. (NYSE: A) is a global leader in life sciences, diagnostics and applied chemical markets. With more than 50 years of insight and innovation, Agilent instruments, software, services, solutions, and people provide trusted answers to its customers’ most challenging questions. The company generated revenues of $4.47 billion in fiscal 2017 and employs 13,500 people worldwide. Information about Agilent is available at www.agilent.com.

Forward-Looking Statements
This news release contains forward-looking statements as defined in the Securities Exchange Act of 1934 and is subject to the safe harbors created therein. The forward-looking statements contained herein include, but are not limited to, information regarding Agilent’s future revenue, earnings and profitability; planned new products; market trends; the future demand for the company’s products and services; customer expectations; and revenue and non-GAAP earnings guidance for the first quarter and full fiscal year 2018. These forward-looking statements involve risks and uncertainties that could cause Agilent’s results to differ materially from management’s current expectations. Such risks and uncertainties include, but are not limited to, unforeseen changes in the strength of our customers’ businesses; unforeseen changes in the demand for current and new products, technologies, and services; unforeseen changes in the currency markets; customer purchasing decisions and timing, and the risk that we are not able to realize the savings expected from integration and restructuring activities.
In addition, other risks that Agilent faces in running its operations include the ability to execute successfully through business cycles; the ability to meet and achieve the benefits of its cost-reduction goals and otherwise successfully adapt its cost structures to continuing changes in business conditions; ongoing competitive, pricing and gross-margin pressures; the risk that our cost-cutting initiatives will impair our ability to develop products and remain competitive and to operate effectively; the impact of geopolitical uncertainties and global economic conditions on our operations, our markets and our ability

2


to conduct business; the ability to improve asset performance to adapt to changes in demand; the ability of our supply chain to adapt to changes in demand; the ability to successfully introduce new products at the right time, price and mix; the ability of Agilent to successfully integrate recent acquisitions; the ability of Agilent to successfully comply with certain complex regulations; and other risks detailed in Agilent’s filings with the Securities and Exchange Commission, including our quarterly report on Form 10-Q for the quarter ended July 31, 2017. Forward-looking statements are based on the beliefs and assumptions of Agilent’s management and on currently available information. Agilent undertakes no responsibility to publicly update or revise any forward-looking statement.

# # #

(1)Non-GAAP net income and non-GAAP earnings per share primarily excludes the impacts of acquisition and integration costs, transformation initiatives, business exit and divestiture costs, and non-cash intangibles amortization. We also exclude any tax benefits or expenses that are not directly related to ongoing operations and which are either isolated or is not expected to occur again with any regularity or predictability. A reconciliation between non-GAAP net income and GAAP net income is set forth on page 6 of the attached tables along with additional information regarding the use of this non-GAAP measure.

(2)Core revenue growth excludes the impact of currency, the NMR business and acquisitions and divestitures within the past 12 months. Core revenue is a non-GAAP measure. A reconciliation between Q4 FY17 GAAP revenue and core revenue is set forth on page 8 of the attached tables along with additional information regarding the use of this non-GAAP measure.

(3)Non-GAAP earnings per share as projected for Q1 FY18 and full fiscal year 2018 excludes primarily the future impact of acquisition and integration costs, transformation costs, non-cash intangibles amortization, and other related costs. We also exclude any tax benefits that are not directly related to ongoing operations and which are either isolated or is not expected to occur again with any regularity or predictability. Most of these excluded amounts that pertain to events that have not yet occurred and are not currently possible to estimate with a reasonable degree of accuracy and could differ materially. Therefore, no reconciliation to GAAP amounts has been provided. Future amortization of intangibles is expected to be approximately $25 million per quarter.

NOTE TO EDITORS: Further technology, corporate citizenship and executive news is available on the Agilent news site at www.agilent.com/go/news.

INVESTOR CONTACT:    

Alicia Rodriguez
+1 408 345 8948
alicia_rodriguez@agilent.com

EDITORIAL CONTACT:

Stefanie Notaney
+1 408 345 8955
stefanie.notaney@agilent.com







3


AGILENT TECHNOLOGIES, INC.
CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS
(In millions, except per share amounts)
(Unaudited)
PRELIMINARY
 
 
 
Three Months Ended
 
 
 
 
October 31,
 
Percent
 
 
2017
 
2016
 
Inc/(Dec)
 
 
 
 
 
 
 
Net revenue
 
$
1,189

 
$
1,111

 
7%
 
 
 
 
 
 
 
Costs and expenses:
 
 
 
 
 
 
Cost of products and services
 
542

 
523

 
4%
Research and development
 
89

 
84

 
6%
Selling, general and administrative
 
325

 
321

 
1%
Total costs and expenses
 
956

 
928

 
3%
 
 
 
 
 
 
 
Income from operations
 
233

 
183

 
27%
 
 
 
 
 
 
 
Interest income
 
7

 
3

 
133%
Interest expense
 
(20
)
 
(19
)
 
5%
Other income (expense), net
 
6

 
(16
)
 
—
 
 
 
 
 
 
 
Income before taxes
 
226

 
151

 
50%
 
 
 
 
 
 
 
Provision for income taxes
 
49

 
25

 
96%
 
 
 
 
 
 
 
Net income
 
$
177

 
$
126

 
40%
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income per share:
 
 
 
 
 
 
Basic
 
$
0.55

 
$
0.39

 
 
Diluted
 
$
0.54

 
$
0.38

 
 
 
 
 
 
 
 
 
Weighted average shares used in computing net income per share:
 
 
 
 
 
 
Basic
 
322

 
324

 
 
Diluted
 
326

 
328

 
 
 
 
 
 
 
 
 
Cash dividends declared per common share
 
$
0.132

 
$
0.115

 
 
 

The preliminary income statement is estimated based on our current information.


1


AGILENT TECHNOLOGIES, INC.
CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS
(In millions, except per share amounts)
(Unaudited)
PRELIMINARY
 
 
 
Years Ended
 
 
 
 
October 31,
 
Percent
 
 
2017
 
2016
 
Inc/(Dec)
 
 
 
 
 
 
 
Net revenue
 
$
4,472

 
$
4,202

 
6%
 
 
 
 
 
 
 
Costs and expenses:
 
 
 
 
 
 
Cost of products and services
 
2,063

 
2,005

 
3%
Research and development
 
339

 
329

 
3%
Selling, general and administrative
 
1,229

 
1,253

 
(2)%
Total costs and expenses
 
3,631

 
3,587

 
1%
 
 
 
 
 
 
 
Income from operations
 
841

 
615

 
37%
 
 
 
 
 
 
 
Interest income
 
22

 
11

 
100%
Interest expense
 
(79
)
 
(72
)
 
10%
Other income (expense), net
 
19

 
(10
)
 
—
 
 
 
 
 
 
 
Income before taxes
 
803

 
544

 
48%
 
 
 
 
 
 
 
Provision for income taxes
 
119

 
82

 
45%
 
 
 
 
 
 
 
Net income
 
$
684

 
$
462

 
48%
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income per share:
 
 
 
 
 
 
Basic
 
$
2.12

 
$
1.42

 
 
Diluted
 
$
2.10

 
$
1.40

 
 
 
 
 
 
 
 
 
Weighted average shares used in computing net income per share:
 
 
 
 
 
 
Basic
 
322

 
326

 
 
Diluted
 
326

 
329

 
 
 
 
 
 
 
 
 
Cash dividends declared per common share
 
$
0.528

 
$
0.460

 
 
 

The preliminary income statement is estimated based on our current information.


2


AGILENT TECHNOLOGIES, INC.
CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME
(In millions)
(Unaudited)
PRELIMINARY
 
 
 
Three Months Ended
 
Years Ended
 
 
 
October 31,
 
October 31,
 
 
 
2017
 
2016
 
2017
 
2016
 
Net Income
 
$
177

 
$
126

 
$
684

 
$
462

 
 
 
 
 
 
 
 
 
 
 
Other comprehensive income (loss), net of tax:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Unrealized gain (loss) on derivative instruments
 
3

 
5

 
—

 
(6
)
 
Amounts reclassified into earnings related to derivative instruments
 
1

 
3

 
(1
)
 
3

 
Foreign currency translation
 
(21
)
 
(49
)
 
40

 
(8
)
 
Net defined benefit pension cost and post retirement plan costs:
 
 
 
 
 
 
 
 
 
Change in actuarial net loss
 
84

 
(115
)
 
118

 
(86
)
 
Change in net prior service benefit
 
(2
)
 
(2
)
 
(6
)
 
(15
)
 
Other comprehensive income (loss)
 
65

 
(158
)
 
151

 
(112
)
 
 
 
 
 
 
 
 
 
 
 
Total comprehensive income (loss)
 
$
242

 
$
(32
)
 
$
835

 
$
350

 
 


The preliminary statement of comprehensive income is estimated based on our current information.


3


AGILENT TECHNOLOGIES, INC.
CONDENSED CONSOLIDATED BALANCE SHEET
(In millions, except par value and share amounts)
(Unaudited)
PRELIMINARY
 
 
October 31,
2017
 
October 31, 2016 (a)
ASSETS
 
 

 
 

Current assets:
 
 

 
 

Cash and cash equivalents
 
$
2,678

 
$
2,289

Accounts receivable, net
 
724

 
631

Inventory
 
575

 
533

Other current assets
 
192

 
182

Total current assets
 
4,169

 
3,635

 
 
 
 
 
Property, plant and equipment, net
 
757

 
639

Goodwill
 
2,607

 
2,517

Other intangible assets, net
 
361

 
416

Long-term investments
 
138

 
135

Other assets
 
397

 
452

Total assets
 
$
8,429

 
$
7,794

 
 
 
 
 
LIABILITIES AND EQUITY
 
 

 
 

 
 
 
 
 
Current liabilities:
 
 

 
 

Accounts payable
 
$
305

 
$
257

Employee compensation and benefits
 
276

 
235

Deferred revenue
 
291

 
269

Short-term debt
 
210

 
—

Other accrued liabilities
 
181

 
184

Total current liabilities
 
1,263

 
945

 
 
 
 
 
Long-term debt
 
1,801

 
1,904

Retirement and post-retirement benefits
 
242

 
360

Other long-term liabilities
 
293

 
339

Total liabilities
 
3,599

 
3,548

 
 
 
 
 
Total Equity:
 
 

 
 

Stockholders' equity:
 
 

 
 

Preferred stock; $0.01 par value; 125 million shares authorized; none issued and outstanding
 
—

 
—

Common stock; $0.01 par value; 2 billion shares authorized; 322 million shares at October 31, 2017 and 614 million shares at October 31, 2016, issued
 
3

 
6

Treasury stock at cost; zero shares at October 31, 2017 and 290 million shares at October 31, 2016
 
—

 
(10,508
)
Additional paid-in-capital
 
5,301

 
9,159

(Accumulated deficit) retained earnings
 
(126
)
 
6,089

Accumulated other comprehensive loss
 
(352
)
 
(503
)
Total stockholders' equity
 
4,826

 
4,243

Non-controlling interest
 
4

 
3

Total equity
 
4,830

 
4,246

Total liabilities and equity
 
$
8,429

 
$
7,794

 
(a) Includes the impact of the adoption of ASU 2015-15 and reclassification of technology and licenses from third parties from other assets to other intangible assets, net.

The preliminary balance sheet is estimated based on our current information.

4


AGILENT TECHNOLOGIES, INC.
CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS
(In millions)
(Unaudited)
PRELIMINARY
 
 
Three Months Ended
 
Years Ended
 
 
 
October 31,
 
October 31,
 
 
 
2017
 
2016
 
2017
 
2016
 
Cash flows from operating activities:
 
 

 
 
 
 
 
 
 
Net income
 
$
177

 
$
126

 
$
684

 
$
462

 
Adjustments to reconcile net income to net cash provided by (used in) operating activities:
 
 
 
 
 
 
 
 
 
Depreciation and amortization
 
52

 
56

 
212

 
246

 
Share-based compensation
 
12

 
11

 
60

 
58

 
Excess and obsolete inventory related charges
 
5

 
4

 
24

 
20

 
Impairment of equity method investment and loans
 
—

 
25

 
—

 
25

 
Other non-cash expenses, net
 
2

 
3

 
7

 
19

 
Changes in assets and liabilities:
 
 
 
 
 
 
 
 
 
Accounts receivable
 
(52
)
 
(52
)
 
(81
)
 
(33
)
 
Inventory
 
(15
)
 
4

 
(61
)
 
(7
)
 
Accounts payable
 
(9
)
 
12

 
2

 
(15
)
 
Employee compensation and benefits
 
49

 
29

 
38

 
15

 
Interest rate swap payments
 
—

 
(10
)
 
—

 
(10
)
 
Other assets and liabilities
 
67

 
26

 
4

 
13

 
Net cash provided by operating activities (a)
 
288

 
234

 
889

 
793

 
 
 
 
 
 
 
 
 
 
 
Cash flows from investing activities:
 
 
 
 
 
 
 
 
 
Investments in property, plant and equipment
 
(58
)
 
(52
)
 
(176
)
 
(139
)
 
Proceeds from sale of investment securities
 
—

 
—

 
—

 
1

 
Payment to acquire cost method investment
 
(1
)
 
—

 
(1
)
 
(80
)
 
Loan to equity method investment
 
—

 
—

 
—

 
(3
)
 
Change in restricted cash and cash equivalents, net
 
(1
)
 
—

 
(1
)
 
245

 
Payment in exchange for convertible note
 
—

 
—

 
(1
)
 
(1
)
 
Proceeds from divestitures
 
1

 
—

 
2

 
—

 
Acquisition of businesses and intangible assets, net of cash acquired
 
(1
)
 
(26
)
 
(128
)
 
(261
)
 
Net cash used in investing activities
 
(60
)
 
(78
)
 
(305
)
 
(238
)
 
 
 
 
 
 
 
 
 
 
 
Cash flows from financing activities:
 
 
 
 
 
 
 
 
 
Issuance of common stock under employee stock plans
 
8

 
3

 
66

 
62

 
Payment of taxes related to net share settlement of equity awards
 
(1
)
 
—

 
(14
)
 
(6
)
 
Payment of dividends
 
(43
)
 
(38
)
 
(170
)
 
(150
)
 
Proceeds from debts and credit facility
 
57

 
—

 
400

 
255

 
Repayment of debts and credit facility
 
(127
)
 
(272
)
 
(290
)
 
(292
)
 
Proceeds from issuance of senior notes
 
—

 
299

 
—

 
299

 
Debt issuance cost
 
—

 
(2
)
 
—

 
(2
)
 
Treasury stock repurchases
 
—

 
(46
)
 
(194
)
 
(434
)
 
Net cash used in financing activities
 
(106
)
 
(56
)
 
(202
)
 
(268
)
 
 
 
 
 
 
 
 
 
 
 
Effect of exchange rate movements
 
(7
)
 
(10
)
 
7

 
(1
)
 
 
 
 
 
 
 
 
 
 
 
Net increase in cash and cash equivalents
 
115

 
90

 
389

 
286

 
 
 
 
 
 
 
 
 
 
 
Cash and cash equivalents at beginning of period
 
2,563

 
2,199

 
2,289

 
2,003

 
Cash and cash equivalents at end of period
 
$
2,678

 
$
2,289

 
$
2,678

 
$
2,289

 
 
 
 
 
 
 
 
 
 
 
(a) Cash payments included in operating activities:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Income tax payments, net
 
$
7

 
$
13

 
$
63

 
$
67

 
Interest payments
 
$
13

 
$
8

 
$
82

 
$
73

 

The preliminary cash flow is estimated based on our current information.

5


AGILENT TECHNOLOGIES, INC.
NON-GAAP NET INCOME AND DILUTED EPS RECONCILIATIONS
(In millions, except per share amounts)
(Unaudited)
PRELIMINARY 
 
 
Three Months Ended
 
Years Ended
 
 
 
October 31,
 
October 31,
 
 
 
2017
 
Diluted
EPS
 
2016
 
Diluted
EPS
 
2017
 
Diluted
EPS
 
2016
 
Diluted
EPS
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
GAAP Net income
 
$
177

 
$
0.54

 
$
126

 
$
0.38

 
$
684

 
$
2.10

 
$
462

 
$
1.40

 
Non-GAAP adjustments:
 
 
 
 
 
 

 
 

 
 
 
 
 
 

 
 

 
Asset impairments
 
—

 
—

 
—

 
—

 
—

 
—

 
4

 
0.01

 
Intangible amortization
 
28

 
0.09

 
32

 
0.10

 
117

 
0.36

 
152

 
0.46

 
Business exit and divestiture costs
 
—

 
—

 
4

 
0.01

 
—

 
—

 
10

 
0.03

 
Transformational initiatives
 
7

 
0.02

 
6

 
0.02

 
12

 
0.04

 
38

 
0.12

 
Acquisition and integration costs
 
5

 
0.02

 
13

 
0.04

 
32

 
0.10

 
41

 
0.12

 
Impairment of investment and loans
 
—

 
—

 
25

 
0.08

 
—

 
—

 
25

 
0.08

 
Pension curtailment gain
 
—

 
—

 
—

 
—

 
—

 
—

 
(15
)
 
(0.05
)
 
Pension settlement gain
 
—

 
—

 
—

 
—

 
(32
)
 
(0.10
)
 
(1
)
 
—

 
Other
 
—

 
—

 
1

 
—

 
5

 
0.02

 
6

 
0.02

 
Adjustment for taxes (a)
 
1

 
—

 
(14
)
 
(0.04
)
 
(50
)
 
(0.16
)
 
(71
)
 
(0.21
)
 
Non-GAAP Net income
 
$
218

 
$
0.67

 
$
193

 
$
0.59

 
$
768

 
$
2.36

 
$
651

 
$
1.98

 

(a) The adjustment for taxes excludes tax benefits that management believes are not directly related to on-going operations and which are either isolated or cannot be expected to occur again with any regularity or predictability. For the three months and year ended October 31, 2017, management uses a non-GAAP effective tax rate of 18.0% for both periods. In the same periods last year, management used a non-GAAP effective tax rate of 16.8% and 19.0%, respectively.

We provide non-GAAP net income and non-GAAP net income per share amounts in order to provide meaningful supplemental information regarding our operational performance and our prospects for the future. These supplemental measures exclude, among other things, charges related to asset impairments, amortization of intangibles, business exit and divestiture costs, transformational initiatives, acquisition and integration costs, impairment of investment and loans, pension curtailment gain and pension settlement gain.

Asset impairments include assets that have been written-down to their fair value.

Business exit and divestiture costs include costs associated with the exit of the NMR business and other business divestitures.

Transformational initiatives include expenses associated with targeted cost reduction activities such as manufacturing transfers, site consolidations, legal entity and other business reorganizations, insourcing or outsourcing of activities. Such costs may include move and relocation costs, one-time termination benefits and other one-time reorganization costs. Included in this category are also expenses associated with the post-separation resizing of the IT infrastructure and streamlining of IT system as well as company programs to transform our product lifecycle management (PLM) system and financial systems.

Acquisition and Integration costs include all incremental expenses incurred to effect a business combination. Such acquisition costs may include advisory, legal, tax, accounting, valuation, and other professional or consulting fees. Such integration costs may include expenses directly related to integration of business and facility operations, the transfer of assets and intellectual property, information technology systems and infrastructure and other employee-related costs.

Impairment of investment and loans include an investment and the related convertible loans that have been written down to their fair value.

Pension curtailment gain resulted from certain retirement plans benefit reductions.

Pension settlement gain resulted from transfer of the substitutional portion of our Japanese pension plan to the government.

Other includes certain legal costs and settlements in addition to other miscellaneous adjustments.

Our management uses non-GAAP measures to evaluate the performance of our core businesses, to estimate future core performance and to compensate employees. Since management finds this measure to be useful, we believe that our investors benefit from seeing our results “through the eyes” of management in addition to seeing our GAAP results. This information facilitates our management’s internal comparisons to our historical operating results as well as to the operating results of our competitors.
 
Our management recognizes that items such as amortization of intangibles can have a material impact on our cash flows and/or our net income. Our GAAP financial statements including our statement of cash flows portray those effects. Although we believe it is useful for investors to see core performance free of special items, investors should understand that the excluded items are actual expenses that may impact the cash available to us for other uses. To gain a complete picture of all effects on the company’s profit and loss from any and all events, management does (and investors should) rely upon the GAAP income statement. The non-GAAP numbers focus instead upon the core business of the company, which is only a subset, albeit a critical one, of the company’s performance.

Readers are reminded that non-GAAP numbers are merely a supplement to, and not a replacement for, GAAP financial measures. They should be read in conjunction with the GAAP financial measures. It should be noted as well that our non-GAAP information may be different from the non-GAAP information provided by other companies.

The preliminary non-GAAP net income and diluted EPS reconciliation is estimated based on our current information.

6


AGILENT TECHNOLOGIES, INC.
SEGMENT INFORMATION
(In millions, except where noted)
(Unaudited)
PRELIMINARY
 
Life Sciences and Applied Markets Group
 
 
Q4'17
 
Q4'16
Revenues
 
$
575

 
$
548

Gross Margin, %
 
61.0
%
 
59.4
%
Income from Operations
 
$
138

 
$
125

Operating margin, %
 
23.9
%
 
22.8
%

Diagnostics and Genomics Group
 
 
Q4'17
 
Q4'16
Revenues
 
$
210

 
$
193

Gross Margin, %
 
55.2
%
 
55.4
%
Income from Operations
 
$
44

 
$
38

Operating margin, %
 
20.8
%
 
19.6
%
 
Agilent CrossLab Group
 
 
Q4'17
 
Q4'16
Revenues
 
$
404

 
$
370

Gross Margin, %
 
49.6
%
 
49.4
%
Income from Operations
 
$
92

 
$
84

Operating margin, %
 
22.9
%
 
22.7
%
 

Income from operations reflect the results of our reportable segments under Agilent's management reporting system which are not necessarily in conformity with GAAP financial measures. Income from operations of our reporting segments exclude, among other things, charges related to asset impairments, amortization of intangibles, business exit and divestiture costs, transformational initiatives, acquisition and integration costs, impairment of investment and loans, pension curtailment gain and pension settlement gain.

Readers are reminded that non-GAAP numbers are merely a supplement to, and not a replacement for, GAAP financial measures. They should be read in conjunction with the GAAP financial measures. It should be noted as well that our non-GAAP information may be different from the non-GAAP information provided by other companies.

The preliminary segment information is estimated based on our current information.

7


AGILENT TECHNOLOGIES, INC.
RECONCILIATION OF REVENUE BY SEGMENT EXCLUDING THE NMR BUSINESS,
ACQUISITIONS, DIVESTITURES AND THE IMPACT OF CURRENCY ADJUSTMENTS (CORE)
(In millions)
(Unaudited)
PRELIMINARY
 
 
Year-over-Year
 




 
 
 
 
 
 
GAAP
 
 
 
 
 
 
GAAP Revenue by Segment
Q4'17
Q4'16
Year-over-Year
% change
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Life Sciences and Applied Markets Group
$
575

$
548

5%
 
 
 




 
 
 
 
 
 
 
 
 
 
 
Diagnostics and Genomics Group
210

193

9%
 
 
 




 
 
 
 
 
 
 
 
 
 
 
Agilent CrossLab Group
404

370

9%
 
 
 




 
 
 
 
 
 
 
 
 
 
 
Agilent
$
1,189

$
1,111

7%
 

 




 
 
 
 
 
 
 
 
 
 
 
 
Non-GAAP
(excluding NMR and Acquisitions)
 
Currency
Adjustments
 
Currency-Adjusted (a)
Non-GAAP Revenue by Segment
Q4'17
Q4'16

Year-over-Year
% change
 
Q4'17
 
Q4'17
Q4'16

Year-over-Year
% change
 
 
 
 
 
 
 
 
 
 
Life Sciences and Applied Markets Group
$
573

$
547

5%
 
$
4

 
$
569

$
547

4%
 
 
 
 
 


 
 
 
 
Diagnostics and Genomics Group
208

193

7%
 
2

 
206

193

7%
 
 
 
 
 
 
 
 
 
 
Agilent CrossLab Group
404

370

9%
 
5

 
399

370

8%
 
 
 
 
 
 
 
 
 
 
Agilent (Core)
$
1,185

$
1,110

7%
 
$
11

 
$
1,174

$
1,110

6%
 
 
 
 
 
 
 
 
 
 
 
.
(a) We compare the year-over-year change in revenue excluding the effect of the NMR business, recent acquisitions and divestitures and foreign currency rate fluctuations to assess the performance of our underlying business. To determine the impact of currency fluctuations, current period results for entities reporting in currencies other than United States dollars are converted into United States dollars at the actual exchange rate in effect during the respective prior periods.

The preliminary reconciliation of GAAP revenue adjusted for the NMR business, recent acquisitions and divestitures and impact of currency is estimated based on our current information.

8